Logo image of EDSA

EDESA BIOTECH INC (EDSA) Stock Fundamental Analysis

USA - NASDAQ:EDSA - CA27966L3065 - Common Stock

2.54 USD
+0.05 (+2.01%)
Last: 10/13/2025, 6:32:40 PM
Fundamental Rating

3

Taking everything into account, EDSA scores 3 out of 10 in our fundamental rating. EDSA was compared to 536 industry peers in the Biotechnology industry. EDSA has a great financial health rating, but its profitability evaluates not so good. EDSA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EDSA has reported negative net income.
In the past year EDSA has reported a negative cash flow from operations.
EDSA had negative earnings in each of the past 5 years.
In the past 5 years EDSA always reported negative operating cash flow.
EDSA Yearly Net Income VS EBIT VS OCF VS FCFEDSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of EDSA (-39.98%) is comparable to the rest of the industry.
EDSA's Return On Equity of -41.89% is fine compared to the rest of the industry. EDSA outperforms 70.90% of its industry peers.
Industry RankSector Rank
ROA -39.98%
ROE -41.89%
ROIC N/A
ROA(3y)-135.86%
ROA(5y)-111.64%
ROE(3y)-205.71%
ROE(5y)-157.84%
ROIC(3y)N/A
ROIC(5y)N/A
EDSA Yearly ROA, ROE, ROICEDSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

EDSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EDSA Yearly Profit, Operating, Gross MarginsEDSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, EDSA has more shares outstanding
EDSA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for EDSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EDSA Yearly Shares OutstandingEDSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
EDSA Yearly Total Debt VS Total AssetsEDSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

2.2 Solvency

An Altman-Z score of 9.16 indicates that EDSA is not in any danger for bankruptcy at the moment.
EDSA has a Altman-Z score of 9.16. This is amongst the best in the industry. EDSA outperforms 82.28% of its industry peers.
There is no outstanding debt for EDSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.16
ROIC/WACCN/A
WACCN/A
EDSA Yearly LT Debt VS Equity VS FCFEDSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 18.97 indicates that EDSA has no problem at all paying its short term obligations.
EDSA's Current ratio of 18.97 is amongst the best of the industry. EDSA outperforms 93.47% of its industry peers.
EDSA has a Quick Ratio of 18.97. This indicates that EDSA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 18.97, EDSA belongs to the best of the industry, outperforming 93.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.97
Quick Ratio 18.97
EDSA Yearly Current Assets VS Current LiabilitesEDSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.07% over the past year.
EPS 1Y (TTM)41.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 1.68% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y37.11%
EPS Next 2Y-5.1%
EPS Next 3Y1.68%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EDSA Yearly Revenue VS EstimatesEDSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 200K 400K 600K 800K 1M
EDSA Yearly EPS VS EstimatesEDSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EDSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EDSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDSA Price Earnings VS Forward Price EarningsEDSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDSA Per share dataEDSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.1%
EPS Next 3Y1.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EDSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EDESA BIOTECH INC

NASDAQ:EDSA (10/13/2025, 6:32:40 PM)

2.54

+0.05 (+2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)12-11 2025-12-11/amc
Inst Owners29.95%
Inst Owner Change0%
Ins Owners23.08%
Ins Owner Change62.68%
Market Cap17.88M
Analysts82.5
Price Target10.54 (314.96%)
Short Float %0.14%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.61%
Min EPS beat(2)0.3%
Max EPS beat(2)6.92%
EPS beat(4)3
Avg EPS beat(4)0.69%
Min EPS beat(4)-51.8%
Max EPS beat(4)47.35%
EPS beat(8)7
Avg EPS beat(8)13.23%
EPS beat(12)11
Avg EPS beat(12)25.78%
EPS beat(16)15
Avg EPS beat(16)23.98%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-34.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.41%
EPS NY rev (1m)0%
EPS NY rev (3m)15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-1.32
EYN/A
EPS(NY)-2.13
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0
BVpS2.01
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.98%
ROE -41.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-135.86%
ROA(5y)-111.64%
ROE(3y)-205.71%
ROE(5y)-157.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.97
Quick Ratio 18.97
Altman-Z 9.16
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.92%
EPS Next Y37.11%
EPS Next 2Y-5.1%
EPS Next 3Y1.68%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.16%
OCF growth 3YN/A
OCF growth 5YN/A